Analyst Price Target is $14.00
▲ +295.48% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Acurx Pharmaceuticals in the last 3 months. The average price target is $14.00, with a high forecast of $14.00 and a low forecast of $14.00. The average price target represents a 295.48% upside from the last price of $3.54.
Current Consensus is
Buy
The current consensus among 2 polled investment analysts is to buy stock in Acurx Pharmaceuticals.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. Its lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. The company is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is based in Staten Island, New York.
Read More